Tag: SARS-CoV-2

Ethnic minorities have less access to COVID-19 vaccines, finds study

With several vaccines already having received Emergency Use Authorization (EUA) against coronavirus disease 2019 (COVID-19), vaccination campaigns have already begun in several countries the world over. However, as with the disease itself, the remedy continues to be plagued by issues of inequity and disparity. A new preprint examines the racial and ethnic differences between COVID-19

Time to implement measures preventing future viral zoonoses

The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally, infecting over 114 million people. The virus first emerged in late December 2019 in Wuhan, China, from a potential animal host. Zoonotic diseases have caused outbreaks throughout history, claiming millions of lives. These diseases occur when pathogens

Single dose of Pfizer BioNTech vaccine reduces asymptomatic infections and potential for SARS-CoV-2 transmission

New data from Addenbrooke’s Hospital in Cambridge suggests that a single dose of the Pfizer BioNTech vaccine can reduce by four-fold the number of asymptomatic SARS-CoV-2 infections. This implies that the vaccine could significantly reduce the risk of transmission of the virus from people who are asymptomatic, as well as protecting others from getting ill.

KAUST researchers develop a safe, fast and cheap testing method to detect viruses

A safe, fast and cheap testing method that uses magnetic nanoparticles to detect viruses in both clinical and wastewater samples has been developed by KAUST researchers. The centrifuge-free approach is compatible with magnetic bead-based automated systems that are already used to process hundreds of samples. Our silica magnetic nanoparticle-based workflow can be assembled from scratch

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

Several genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have risen to prominence during the course of the coronavirus disease 2019 (COVID-19) pandemic, one of which is the UK variant – termed B.1.1.7 by the Centers for Disease Control and Prevention (CDC). This variant is associated with increased transmissibility compared to the wild-type

Current monoclonal antibodies less potent against SARS-CoV-2 variants

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc across the globe. Scientists are racing to develop effective therapeutic regimens to combat the infection. One of therapy currently used to stimulate a robust immune response against the virus is monoclonal antibodies, a treatment used for

COVID-19 and lung cancer have a common pathway, say researchers

The coronavirus disease 2019 (COVID-19) is a transmissible viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the ongoing global pandemic. The virus was first detected in Wuhan, China, at the end of 2019 and to date has caused over 109 million infections worldwide. With over 2.4 million

Immune response to SARS-CoV-2 may be limited by a set of genes

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School of Medicine report that individual

Detection of emerging SARS-CoV-2 variant in New York

Researchers at the California Institute of Technology in Pasadena have developed a software tool called "Variant Database" that has detected an emerging lineage of severe acute respiratory coronavirus 2 (SARS-CoV-2) isolates in New York. The novel SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to sweep the globe

CDC says vaccinated individuals can skip COVID quarantines

The coronavirus disease (COVID-19) pandemic's global case toll has surpassed 109 million globally. Of these infections, 2.4 million people have already succumbed to the disease. As the pandemic continues to spread, many countries have rolled out vaccinations. Now, the U.S. Centers for Disease Control and Prevention (CDC) has issued updated guidance that people who have

Researchers report a new SARS-CoV-2 variant of concern in Uganda

The etiological agent of the coronavirus disease 2019 (COVID-19) – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – was first identified in Wuhan, China, in December 2019. Since then, the virus has infected more than 107 million people worldwide and caused over 2.4 million deaths. Due to its high transmissibility, it has been difficult to

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

Researchers in the United States who tracked the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient found that convalescent plasma therapy was associated with the emergence of viral variants that were less susceptible to neutralizing antibodies. The SARS-CoV-2 virus is the agent responsible for the coronavirus 2019 (COVID-19) pandemic that

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

The coronavirus disease 2019 (COVID-19) pandemic continues to spread across the globe. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the disease exhibits an array of clinical outcomes (from asymptomatic to critical). The majority of cases are asymptomatic or minimally symptomatic, wherein there are no symptoms or only a few manageable ones.

Subgenomic RNAs could help identify asymptomatic SARS-CoV-2 infection

With new variants emerging, often showing increased transmissibility and virulence, governments and health organizations do not appear to be within striking distance of effectively containing the ongoing coronavirus disease 2019 (COVID-19) pandemic. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this condition presents with a wide spectrum of severity, ranging from asymptomatic infection

What are Coronaviruses?

Skip to: What are coronaviruses? Why are coronaviruses dangerous? SARS-CoV-2 / COVID-19 SARS-CoV MERS-CoV The rapid spread of the virus that causes the coronavirus disease (COVID-19) has sparked alarm across the globe. The World Health Organization (WHO) has declared the condition a global pandemic, with many countries grappling with the rise of infections. The disease

The Naming System Behind SARS-CoV-2

SARS-CoV-2 stands for severe acute respiratory syndrome coronavirus 2. It is a virus that causes respiratory illness in humans. It passed from animals to humans in a mutated form and was first reported in December 2019 in an outbreak occurring in Wuhan, China. Image Credit: Kateryna Kon/Shutterstock.com This virus has since rapidly spread throughout the

Some transmission of SARS-CoV-2 occurs after seven, 10 days

There is some onward transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from household contacts released from quarantine after seven or 10 days, according to research published in the Jan. 1 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Melissa A. Rolfes, Ph.D., from the CDC COVID-19